



For further information:  
Consuelo Trillo Díaz  
[ctrillo@rovi.es](mailto:ctrillo@rovi.es)  
Tel: + 34 91 244 44 10

## **INCORPORATION OF TWO DOCTORS TO THE R&D&i WITHIN THE "TORRES QUEVEDO" PROGRAM 2015 TENDER**

**Madrid – 09 of February 2017**

ROVI is a company committed to innovation, with more than 414 granted patents and 137 applications in process). Currently, R&D projects of ROVI are mainly focused in glycomics and ISM<sup>®</sup> platform, the latter is a drug release system, owned by ROVI, whose objective is improving patient's adherence to treatment.

ROVI has received the support of the Ministry of Economy and Competitiveness in its Research and Development work through the TORRES QUEVEDO program. This program promotes the recruitment of doctors to develop industrial research projects, experimental development or feasibility studies, in order to promote the professional career of investigators, as well as to stimulate demand, in the private sector, of well trained personnel to undertake R&D plans and projects, and help to consolidate newly created technological companies.

Thanks to the funding received, the staff has been strengthened through the recruitment of two university doctors for the implementation of the R&D&i activity within the framework of the projects **"Clinical research of the technological for the development of (ISM<sup>®</sup>, In Situ Microparticles)" medicine products** and **"Assessment of effectiveness of Risperidone ISM<sup>®</sup> in adult patients with acute exacerbation of schizophrenia"**, Reference n<sup>o</sup>. of files: **PTQ-15-07720 and PTQ-15-07457**.



## About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI's research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISM® technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company's website: [www.rovi.es](http://www.rovi.es)